High-Grade Glioma: Abemaciclib with Temozolomide

We are studying whether adding abemaciclib to temozolomide helps children and young adults with newly diagnosed high-grade glioma after radiotherapy. This trial compares the combination treatment to temozolomide alone.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Verzenios
Verzenios is a medicine used to treat certain types of advanced or metastatic breast cancer.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Abemaciclib
Abemaciclib is a substance that slows growth of certain breast cancer cells by blocking proteins that help them divide.
Temozolomide
Temozolomide is a substance used in chemotherapy to treat certain types of brain tumors by slowing cancer cell growth.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
UZ Leuven
Pediatric hemato-oncology department
Heverlee, Belgium
Universitair Ziekenhuis Gent
Pediatric hemato- oncology department
Ledeberg, Belgium
Centre Hospitalier Regional De La Citadelle
Pediatric hemato-oncology department
Liège, Belgium

Sponsor: Eli Lilly & Co.
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.